Seattle Genetics Inc.

(SGEN) Trade

By |

Profile

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website: www.seattlegenetics.com
Email: ppinkston@seagen.com
Main Phone: +1 425 527-4000
Address: 21823 - 30th Drive South East
Address 2: Building 3
State: WA
City / Town: Bothell
Country: US
Postal Code: 98021

Issuer Information

Exchange: NGS
CEO: Clay B. Siegall
Employees: 1605
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More

Profile

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website: www.seattlegenetics.com
Email: ppinkston@seagen.com
Main Phone: +1 425 527-4000
Address: 21823 - 30th Drive South East
Address 2: Building 3
State: WA
City / Town: Bothell
Country: US
Postal Code: 98021

Issuer Information

Exchange: NGS
CEO: Clay B. Siegall
Employees: 1605
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
$ 179.43 $ 0.16 (0.09%)
Last Price 179.43 Change $ 0.16 Change % 0.09 Tick N/A
Bid 173.25 Bid Size 100.00 Ask 180.00 Ask Size 200.00
Open 177.99 High 179.81 Low 174.48 Prev Close 179.27
Last Trade Volume 780,780 52 Wk Hi 187.99 52 Wk Low 72.27
Market Cap 31.2 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 173,996,620.00 EPS (TTM) -1.48 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 52 170
Number of Buys 41 106
Number of Sells 11 64
Net Activity 1537290 5601762
Last 10 Buys Shares
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Darren S. Cline 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Darren S. Cline 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 77 77 77 80
Low Target Price Estimate 50 50 50 50
Mean Target Price Estimate 64.82 64.64 64.64 66.64
Standard Deviation 9.23 9.31 9.31 10.11
Date of Most Recent Estimate 06/04/18 05/17/18 05/17/18 06/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 5 5 6
Moderate Buy 2 2 3 3
Hold 5 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.92 2.08 2.04 1.97